Avalon Pharma profit up 21% to SAR 79.9M in 2024; Q4 at SAR 44.8M

Middle East Pharmaceutical Industries Co. (Avalon Pharma) posted a net profit of SAR 79.9 million for 2024, a rise of 21% from SAR 65.8 million a year earlier.

Financials (M)

Item	2023	2024	Change‬
Revenues	338.44	394.00	16.4 %
Gross Income	204.02	243.36	19.3 %
Operating Income	78.68	89.88	14.2 %
Net Income	65.83	79.85	21.3 %
Average Shares	20.00	20.00	-
Earnings Per Share before unusual items	3.29	3.99	21.3 %
EPS (Riyals)	3.29	3.99	21.3 %

Current Quarter Comparison (M)

Compared With The

Item	Q4 2023	Q4 2024	Change‬
Revenues	129.17	135.99	5.3 %
Gross Income	83.39	85.79	2.9 %
Operating Income	48.82	46.26	(5.2 %)
Net Income	45.40	44.81	(1.3 %)
Average Shares	20.00	20.00	-
Earnings Per Share before unusual items	2.27	2.24	(1.3 %)
EPS (Riyals)	2.27	2.24	(1.3 %)

Item	Q3 2024	Q4 2024	Change‬
Revenues	81.06	135.99	67.8 %
Gross Income	46.77	85.79	83.4 %
Operating Income	6.69	46.26	591.9 %
Net Income	3.87	44.81	1058.6 %
Average Shares	20.00	20.00	-
Earnings Per Share before unusual items	0.19	2.24	1058.6 %
EPS (Riyals)	0.19	2.24	1058.6 %

View More Financial Results

View other reports

Share Price

Middle East Pharmaceutical Industries Co. (AVALON PHARMA)

	Current
Market Cap (M Riyal)	2,592.00
Enterprise Value (EV) (M)	2,634.83
Shares Outstanding ((M))	20.00
EPS ( Riyal) (TTM)	3.99
Book Value (BV) ( Riyal)	18.41
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	32.46
P/E (TTM)	32.46
Price/book	7.04
Return on Average Assets (%) (TTM)	16.3
Return on Average Equity (%) (TTM)	19.5

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	-	-	-	-	-	-
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	232.09	-	147.13	-	60.35	-
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	301.66	30.0 %	176.38	19.9 %	79.33	31.5 %
Q1 2021	-	-	-	-	-	-
Q2 2021	-	-	-	-	-	-
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	287.22	(4.8 %)	174.58	(1.0 %)	74.76	(5.8 %)
Q1 2022	49.67	-	29.30	-	(0.21)	-
Q2 2022	83.23	-	48.52	-	23.55	-
Q3 2022	-	-	-	-	-	-
Q4 2022	-	-	-	-	-	-
2022	302.66	5.4 %	184.29	5.6 %	70.34	(5.9 %)
Q1 2023	55.23	11.2 %	33.74	15.1 %	2.96	1522.2 %
Q2 2023	93.29	12.1 %	52.67	8.5 %	20.88	(11.4 %)
Q3 2023	60.75	-	34.23	-	6.03	-
Q4 2023	129.17	-	83.39	-	48.82	-
2023	338.44	11.8 %	204.02	10.7 %	78.68	11.9 %
Q1 2024	75.82	37.3 %	46.46	37.7 %	12.43	320.1 %
Q2 2024	101.13	8.4 %	64.34	22.2 %	24.51	17.4 %
Q3 2024	81.06	33.4 %	46.77	36.7 %	6.69	10.8 %
Q4 2024	135.99	5.3 %	85.79	2.9 %	46.26	(5.2 %)
2024	394.00	16.4 %	243.36	19.3 %	89.88	14.2 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	-	-	-	-	-	-
2019	232.09	-	147.13	-	60.35	-
2020	301.66	30.0 %	176.38	19.9 %	79.33	31.5 %
2021	287.22	(4.8 %)	174.58	(1.0 %)	74.76	(5.8 %)
2022	302.66	5.4 %	184.29	5.6 %	70.34	(5.9 %)
2023	338.44	11.8 %	204.02	10.7 %	78.68	11.9 %
2024	394.00	16.4 %	243.36	19.3 %	89.88	14.2 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	-	-	-	-	-	-
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	54.05	-	2.70	-	54.05	2.70
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	72.81	34.7 %	3.64	-	72.81	3.64
Q1 2021	-	-	-	-	-	-
Q2 2021	-	-	-	-	-	-
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	66.28	(9.0 %)	3.31	-	66.28	3.31
Q1 2022	(2.57)	-	(0.13)	-	(2.57)	(0.13)
Q2 2022	20.24	-	1.01	-	20.24	1.01
Q3 2022	-	-	-	-	-	-
Q4 2022	-	-	-	-	-	-
2022	59.45	(10.3 %)	2.97	-	59.45	2.97
Q1 2023	(0.50)	80.6 %	(0.02)	-	(0.50)	(0.02)
Q2 2023	18.04	(10.9 %)	0.90	-	18.04	0.90
Q3 2023	2.88	-	0.14	-	2.88	0.14
Q4 2023	45.40	-	2.27	-	45.40	2.27
2023	65.83	10.7 %	3.29	-	65.83	3.29
Q1 2024	9.37	1987.0 %	0.47	-	9.37	0.47
Q2 2024	21.81	20.8 %	1.09	-	21.81	1.09
Q3 2024	3.87	34.4 %	0.19	-	3.87	0.19
Q4 2024	44.81	(1.3 %)	2.24	-	44.81	2.24
2024	79.85	21.3 %	3.99	-	79.85	3.99

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	-	-	-	-	-	-
2019	54.05	-	2.70	-	54.05	2.70
2020	72.81	34.7 %	3.64	-	72.81	3.64
2021	66.28	(9.0 %)	3.31	-	66.28	3.31
2022	59.45	(10.3 %)	2.97	-	59.45	2.97
2023	65.83	10.7 %	3.29	-	65.83	3.29
2024	79.85	21.3 %	3.99	-	79.85	3.99

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
2019	63.39 %	29.75 %	23.29 %
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
2020	58.47 %	29.24 %	24.14 %
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
2021	60.78 %	29.36 %	23.08 %
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	-	-	-
2022	60.89 %	26.75 %	19.64 %
Q1 2023	-	-	-
Q2 2023	-	-	-
Q3 2023	-	-	-
Q4 2023	60.28 %	26.77 %	19.45 %
2023	60.28 %	26.77 %	19.45 %
Q1 2024	60.37 %	27.99 %	21.08 %
Q2 2024	62.26 %	28.52 %	21.66 %
Q3 2024	62.24 %	27.51 %	20.78 %
Q4 2024	61.77 %	26.83 %	20.27 %
2024	61.77 %	26.83 %	20.27 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	63.39 %	29.75 %	23.29 %
2020	58.47 %	29.24 %	24.14 %
2021	60.78 %	29.36 %	23.08 %
2022	60.89 %	26.75 %	19.64 %
2023	60.28 %	26.77 %	19.45 %
2024	61.77 %	26.83 %	20.27 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	59.00 %	-	(5.17 %)
Q2 2022	58.30 %	-	24.32 %
Q3 2022	-	-	-
Q4 2022	-	-	-
Q1 2023	61.09 %	10.61 %	(0.90 %)
Q2 2023	56.45 %	25.56 %	19.34 %
Q3 2023	56.34 %	14.82 %	4.73 %
Q4 2023	64.56 %	40.18 %	35.15 %
Q1 2024	61.27 %	20.74 %	12.36 %
Q2 2024	63.62 %	27.69 %	21.56 %
Q3 2024	57.70 %	13.44 %	4.77 %
Q4 2024	63.08 %	37.57 %	32.95 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	-	-	-	-
Q2 2018	-	-	-	-
Q3 2018	-	-	-	-
Q4 2018	-	-	-	-
Q1 2019	-	-	-	-
Q2 2019	-	-	-	-
Q3 2019	-	-	-	-
Q4 2019	-	-	-	-
Q1 2020	-	-	-	-
Q2 2020	-	-	-	-
Q3 2020	-	-	-	-
Q4 2020	-	-	-	-
Q1 2021	-	-	-	-
Q2 2021	-	-	-	-
Q3 2021	-	-	-	-
Q4 2021	-	-	-	-
Q1 2022	20.00	-	-	-
Q2 2022	20.00	-	-	13.17
Q3 2022	-	-	-	-
Q4 2022	-	-	-	-
Q1 2023	20.00	-	-	13.50
Q2 2023	20.00	-	-	13.87
Q3 2023	20.00	-	-	13.64
Q4 2023	20.00	3.29	3.29	15.32
Q1 2024	20.00	3.78	3.78	15.77
Q2 2024	20.00	3.97	3.97	16.86
Q3 2024	20.00	4.02	4.02	16.31
Q4 2024	20.00	3.99	3.99	18.41

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	-	-	-	-
2016	-	-	-	-
2017	-	-	-	-
2018	-	-	-	-
2019	20.00	2.70	2.70	10.87
2020	20.00	3.64	3.64	12.62
2021	20.00	3.31	3.31	13.35
2022	20.00	2.97	2.97	14.01
2023	20.00	3.29	3.29	15.32
2024	20.00	3.99	3.99	18.41

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	-	-	-
Q1 2023	-	-	-
Q2 2023	-	-	-
Q3 2023	-	-	-
Q4 2023	-	-	-
Q1 2024	38.68	38.68	9.28
Q2 2024	33.13	33.13	7.81
Q3 2024	34.81	34.81	8.58
Q4 2024	30.51	30.51	6.62

Period	P/E	Adjusted P/E	Price/book
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	-	-	-
2021	-	-	-
2022	-	-	-
2023	-	-	-
2024	30.51	30.51	6.62

Business Segments (Million)

Compared With The

Period	Private customers	Public Customers	Export customers
Q1 2022	36.71	10.47	2.49
Q2 2022	63.55	15.92	3.76
Q1 2023	42.36	9.32	3.55
Q2 2023	69.28	16.65	7.36
Q3 2023	41.03	15.25	4.47
Q4 2023	92.66	14.68	21.83
Q1 2024	54.78	12.11	8.94
Q2 2024	71.78	18.08	11.28
Q3 2024	41.77	26.88	12.41
Q4 2024	99.97	18.62	17.40

Period	Private customers	Public Customers	Export customers
2019	158.40	52.57	21.13
2020	190.92	88.16	22.58
2021	194.14	65.64	27.44
2022	207.97	68.58	26.11
2023	245.32	55.91	37.22
2024	268.29	75.68	50.03

Analysts Estimates (Million)

Item	Q4 2024 (e)	Q4 2024 (net income)	Change‬
Average	50.36	44.81	(11.0 %)

Estimates vs Actual (Million)

Item	Q4 2024 (e)	Q4 2024 (net income)	Change
Al Rajhi Capital	49.00	44.81	(8.6) %
SNB Capital	49.10	44.81	(8.7) %
GIB Capital	50.00	44.81	(10.4) %
OSOOL AND BAKHEET	53.34	44.81	(16.0) %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Avalon Pharma profit up 21% to SAR 79.9M in 2024; Q4 at SAR 44.8M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Middle East Pharmaceutical Industries Co. (AVALON PHARMA)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Avalon Pharma profit up 21% to SAR 79.9M in 2024; Q4 at SAR 44.8M

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Middle East Pharmaceutical Industries Co. (AVALON PHARMA)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2024

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)